COVID-19 alert: Read about changed restrictions for businesses in Greater Brisbane from 6pm, Monday 11 January.
Novel hand, foot and mouth disease (HFMD) therapeutics
Hand, foot and mouth disease (HFMD) infects millions of children around the world each year and can present as a mild disease through to severe neurological disease. Griffith University's Institute for Glycomics has developed potent small molecule inhibitors for HFMD.
Unique selling point/competitive advantage
There are currently no drugs on the market to treat mild or severe HFMD. The lead drug candidate from Griffith University's Institute for Glycomics inhibits the virus at clinically relevant nanomolar concentrations and is an order of magnitude more potent than the best published inhibitor.
The research team has extensive drug discovery, translation and commercialisation expertise.
Investment or collaboration opportunities
Griffith University's Institute for Glycomics is seeking a company partner to co-develop their carbohydrate-based small molecule candidates through lead optimisation and preclinical stages.
An option to an exclusive global licence is available.
Intellectual property rights
Griffith University has proprietary rights for composition of matter and a patented synthetic method to prepare lead molecules.
Dr Chris Davis
Phone: +61 7 555 27033
Visit Griffith University - Institute for Glycomics for more information for investors.
- Last reviewed: 17 Jul 2019
- Last updated: 25 Jul 2019